Medigus: Polyrizon to Test its Product Candidate for Protection Against High Transmissible Corona Virus Delta Variant B.1.617.2
September 09 2021 - 7:45AM
Medigus Ltd. (Nasdaq: MDGS), a technology company engaged in
advanced medical solutions, innovative internet technologies and
electric vehicle and charging solutions, today announced that
Polyrizon Ltd., a privately held company which Medigus owns 35.86%
of its share capital, will evaluate the viral infection prophylaxis
effect of its innovative product candidate against the Delta
variant of the coronavirus(lineage B.1.617.2), in-vitro. This study
follows recent pre-clinical studies showed strong potential against
human coronavirus 229E and influenza virus infection.
The Delta variant has mutations in the gene
encoding the SARS-CoV-2 spike protein causing the substitutions
T478K, P681R and L452R, which are known to affect transmissibility
of the virus. As a result, the Delta variant has been found to be
more contagious than the other coronavirus strains.
In the upcoming study, Polyrizon will assess the
protection effect of its Capture and Contain (C&C™) platform
against the highly transmissible Delta variant. The study is
planned to begin in Q4 2021.
The predominant COVID-19 Delta strain has put
the focus back on transmission prevention where layered prevention
solutions are needed to reduce the transmission of the Delta
variant. Polyrizon’s C&C™ platform focuses on preventative
approaches that when combined with vaccination, social distancing
and mask usage should further decrease the risk of infection.
Last week, Polyrizon submitted an additional
patent application to the United States Patent and Trademark Office
for its innovative technology.
The invention generally pertains to the field of
hydrogels that are capable of capturing and containing biological
assaults intrusion through the upper airways and eye cavities.
Furthermore, the invention details a novel modality for a delivery
system for drugs through the nasal mucosa that may be able to
deliver a higher drug dosage into the body and reside longer in the
nasal cavity.
About Medigus
Based in Israel, Medigus Ltd. (Nasdaq: MDGS) is
a technologies company that is focused on innovative growth
partnerships, mainly in advanced medical solutions, digital
commerce, and electric vehicle markets. Medigus' affiliations in
the medical solutions arena consist of ownership in ScoutCam
(OTCQB: SCTC), Inc, and Polyzion, LTD. The Company’s affiliates in
digital commerce include Gix Internet Ltd. (TASE:GIX), Jeff's
Brands and Eventer Technologies, Ltd. In the electric vehicle
market, Charging Robotics, Ltd. and Revolz are also part of the
Company’s portfolio of technology solution providers. Medigus is
traded on the Nasdaq Capital Market. To learn more about Medigus’
advanced technologies, please
visit http://www.medigus.com/investor-relations.
Cautionary Note Regarding Forward Looking
Statements
This press release may contain statements that
are “Forward-Looking Statements,” which are based upon the current
estimates, assumptions and expectations of Medigus’ management and
its knowledge of the relevant market. The company has tried, where
possible, to identify such information and statements by using
words such as “anticipate,” “believe,” “envision,” “estimate,”
“expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,”
“potential,” “will,” “would,” “could,” “should,” “continue,”
“contemplate” and other similar expressions and derivations thereof
in connection with any discussion of future events, trends or
prospects or future operating or financial performance, although
not all forward-looking statements contain these identifying words.
For example, Medigus uses forward looking statements when
describing Polyrizon’s upcoming study. These forward-looking
statements represent Medigus’ expectations or beliefs concerning
future events, and it is possible that the results described in
this press release will not be achieved. By their nature,
Forward-Looking Statements involve known and unknown risks,
uncertainties and other factors which may cause future results of
the Medigus’ activity to differ significantly from the content and
implications of such statements. Other risk factors affecting
Medigus and Polyrizon are discussed in detail in the
Medigus’ filings with the Securities and Exchange Commission.
Forward-Looking Statements are pertinent only as of the date on
which they are made, and Medigus undertakes no obligation to update
or revise any Forward-Looking Statements, whether as a result of
new information, future developments or otherwise. Neither Medigus
nor its shareholders, officers and employees, shall be liable for
any action and the results of any action taken by any person based
on the information contained herein, including without limitation
the purchase or sale of Medigus’ securities. Nothing in this press
release should be deemed to be medical or other advice of any
kind.
Contact
Tali Dinar
Chief Financial Officer
+972-8-6466-880
ir@medigus.com
Medigus (NASDAQ:MDGS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Medigus (NASDAQ:MDGS)
Historical Stock Chart
From Sep 2023 to Sep 2024